NK cell therapy SNK01 slows Alzheimer's cognitive decline in Phase 1 trial
SNK01, an NK cell therapy by NKGen Biotech, appears safe and well tolerated and may be of cognitive benefit in Alzheimer’s disease.| Alzheimer's News Today
SNK01, an NK cell therapy by NKGen Biotech, appears safe and well tolerated and may be of cognitive benefit in Alzheimer’s disease.| Alzheimer's News Today
The Phase 2 study will further assess SNK01's safety and its efficacy in about 30 patients who'll receive it every three weeks up to a year.| Alzheimer's News Today
